Bernstein Report: AI Drug Discovery Faces 3-5 Year Reality Check

A Bernstein report on the U.S. biopharmaceutical industry reveals that approximately 70 AI-derived projects have entered clinical trials, though most remain in early stages. While tech leaders like Demis Hassabis and Dario Amodei suggest rapid breakthroughs, Bernstein emphasizes that biological validation in humans cannot be compressed by algorithms. The report highlights that increasing success rates is more valuable than merely accelerating timelines. Major pharmaceutical companies are adopting diverse strategies: Eli Lilly leads in partnership breadth, A